Gedeon Richter acquires Grünenthal's Belara
This article was originally published in Scrip
Executive Summary
Gedeon Richter is acquiring Grünenthal's portfolio of oral contraceptives including Belara (chlormadinone acetate plus ethinyl estradiol) for €236.5 million, part of which Richter said it would borrow. The transaction is subject to Germany's antitrust authority's approval which is expected at the end of this year.